CDKN2B and acute myeloid leukemia: Hypermethylation of p15 promoter occurs in approximately 50% of patients with chronic myeloid leukemia (CML), AML, and acute lymphoblastic leukemia (ALL) and represents a key feature of the malignant progression of MDS [16].